Delivery Order SPE2DB25D3022-SPE2DB25FWCDK
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,591.96 to AmerisourceBergen Drug Corp on November 4, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, an injectable medication used to treat autoimmune conditions. This firm fixed-price delivery order, with completion scheduled for November 5, 2025, represents a direct purchase under a competitive procurement process with no set-aside designation. The product will be delivered to AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $4,656.85 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, a injectable medication used to treat autoimmune conditions. This contract, awarded on October 21, 2025, with an ultimate completion date of October 22, 2025, is a firm fixed price delivery order with no set-aside designation. The work will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $5,330.07 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a injectable medication used to treat autoimmune conditions. The contract, with an ultimate completion date of September 10, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. This award was made on a competitive basis with no...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used in the treatment of autoimmune conditions. This competitively awarded, non-set-aside delivery order carries a firm fixed price ceiling value of $7,652.27 and is scheduled for completion by September 16, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,265.90 delivery order on July 18, 2025, for HUMIRA (CF) Pen 40 mg/0.4 mls, with completion scheduled for July 21, 2025. This competitive award, issued under firm fixed pricing with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical product...
- AmerisourceBergen Drug Corp has been awarded a delivery order by the Defense Logistics Agency (DLA) for HUMIRA Pen 40 mg/0.8 mL, a biologic medication used to treat autoimmune conditions. The contract, valued at $2,265.90, was awarded on September 9, 2025, with an ultimate completion date of September 10, 2025. This is a firm fixed-price delivery order issued under a non-set-aside procurement, reflecting open competition. The place of performance is listed as AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $9,883.59 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 21, 2025, with an ultimate completion date of August 22, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered from...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL with a ceiling value of $1,185.69. This is a firm fixed price delivery order under a non-set-aside competitive procurement. The contract is set to be completed by August 26, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a injectable pharmaceutical treatment for autoimmune conditions. This firm fixed-price delivery order carries a ceiling value of $9,950.72 and is scheduled for completion by June 3, 2025. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 18, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a prescription medication used to treat autoimmune conditions. This firm fixed-price delivery order, valued at $13,730.83, is scheduled for completion by November 19, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award utilized no set-aside designation and was competitively awarded through...
- SPE2DB25D3022Indefinite Delivery Contract
- SPE2DB25D3022-SPE2DB25FWCDKDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a injectable medication used to treat autoimmune conditions. This firm fixed price delivery order, valued at $1,425.83, represents a non-set-aside competitive award and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under a child contract vehicle, reflecting AmerisourceBergen's role as a critical pharmaceutical distributor within the federal medical supply chain. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as the parent contract vehicle for this delivery order. This comprehensive pharmaceutical prime vendor contract enables AmerisourceBergen to supply a broad range of medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs globally, including the Defense Health Agency and U.S. Coast Guard. The company's demonstrated capability to fulfill federal medical procurement requirements through competitive awards, combined with its extensive pharmaceutical portfolio across multiple therapeutic domains, positions it as a key vendor for federal medical supply needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 8/5/25 |